副教授

卢玺峰

 

姓名:卢玺峰

职位:副教授,研究生导师

邮箱:x.lu@szu.edu.cn

简介:

博士,深圳大学医学部生理学系副教授,独立PI。长期从事肾素-血管紧张素-醛固酮系统、血压稳态调控、脂代谢和能量代谢调控的机制研究。近年来在国际知名期刊Circulation Research、Organic Letters、Nature Review Nephrology、Pharmacological Research、Journal of Hypertension、AJP-Renal Physiology等杂志发表论文14篇;申请国家发明专利1项。主持国家自然科学基金青年基金1项,国家自然科学基金面上项目1项,省市级项目3项;深圳市海外高层次人才计划C类;获深圳大学“荔园优青”项目支持。目前担任Journal of Renin-Angiotensin-System以及American Journal of Hypertension杂志的审稿人。

 

研究方向

脂代谢紊乱的机制研究

能量代谢调控的机制研究

 

科研项目

 1.国家自然科学基金面上项目,受体阻断脂肪肝发生的关键机制:调节肝脏-脂肪交互对话?8187060557万,2019/1-2022/12,在研,主持

2.国家自然科学基金面上项目,中性粒细胞来源的颗粒蛋白Proteinase 3 通过调节肝脏-肠道菌群轴介导非酒精性脂肪肝炎的研究,815704091558万,2016/1-2019/12,在研,第一参与人

3.国家自然科学基金青年项目,肾素(原)受体在LDL受体功能调节中的关键作用:一个血脂调节的新机制,81500667,18万,2016/1-2018/12,已结题,主持

4.深圳市基础项目,肾素(原)受体调节体内LDLR 及血脂水平的研究,JCYJ20160307160819191,30万,2016/7-2018/6,已结题,主持

5.深圳市基础项目,糖代谢紊乱影响糖尿病肾病进展的机制研究,JCYJ2017081709392850830万,2018/3-2020/3,在研,主持

6.深圳市基础项目,代谢性炎症与脂代谢紊乱性疾病的基础研究,JCYJ20140509172719310,2015/1-2016/12;已结题,参与

7.深圳大学科研启动项目,肾素(原)受体的新功能:调节脂蛋白代谢,2015/6-2017/5;已结题,主持

8.广东省医学科学技术研究基金面上项目,肾素(原)受体在糖尿病肾病的发生发展中的作用,A2015051,1万,2015/7-2017/6,已结题,主持

 

代表性成果

1. Ren L, Lu X, Danser A H J. Revisiting the Brain Renin-Angiotensin System-Focus on Novel Therapies [J]. Curr Hypertens Rep, 2019, 21(4): 28.

2. Fan M, Wen Y, Ye D, Jin Z, Zhao P, Chen D, Lu X, He Q. Acid-Responsive H2 -Releasing 2D MgB2 Nanosheet for Therapeutic Synergy and Side Effect Attenuation of Gastric Cancer Chemotherapy [J]. Adv Healthc Mater, 2019, 8(13): e1900157.

3. Zhao P, Jin Z, Chen Q, Yang T, Chen D, Meng J, Lu X, Gu Z, He Q. Local generation of hydrogen for enhanced photothermal therapy. Nature Communications, 2018, 9(1): 4241.

4.Liu, J., Liu, Y., Yan, Y., Yang, J., Lu, X., Cheng, Y. Commiphoratones A and B, Two Sesquiterpene Dimers from Resina Commiphora. Organic Letters. 20 (8). 2018.

5.Song, Y., Liu, Y., Yan, Y., Lu, X., Cheng, Y. Phenolic Compounds from Belamcanda chinesis Seeds. Molecules. 2018.3.5.

6.Ren, L., Sun Y., Ruan, X., Lu, X. (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice from Diet-induced Obesity and Hepatsteatosis. Circ Res. 2018.3.2,122(5):730-741.

7.  Hu, X., Qin, Fu., Lu, X., Cheng, Y. Three New Polyynes from Codonopsis pilosula and Their Activities on Lipid Metabolism. Molecules. 2018. 23(4).

8.Yang, X., Okamura, D., Lu, X., Chen, Y., Moorhead, J., Varghese, Z., Ruan, X. CD36 in Chronic Kidney Disease: Novel Insights and Therapeutic Opportunities. Nature Reviews Nephrology. 2017.12,13(12):769:781.

9.Sun, Y., Danser, AHJ., Lu, X. (Pro) renin Receptor as a Therapeutic Target for the treatment of Cardiovascular Diseases? Pharmacological Research. 2017.7.125:48-56.

10.Zhu, X., Yan, Y., Ai, C., Jiang, S., Xu, S., Niu, M., Wang, X., Zhong, G., Lu, X., Xue, Y., Tian, S., Li, G., Tang, S., Jiang., Y. Jarid2 is essential for the maintenance of tumor initiating cells in bladder cancer. Oncotarget. 2017. 11; 8(15): 24483–24490.

11.Chen, D., Zhu, X., Yan, Y., Ai, C., Lu, X., Xu, S., Jiang, S., Zhong, G., Chen, D., Jiang., Y. Long Non-coding RNA HoxA-AS3 interacts with EZH2 to Regulate Lineage Commitment of Mesenchymal Stem Cells. Oncotarget. 2016. 7(39):63561-63570

12.Daryadel, A., Bourgeois, S., Figueiredo, MF., Gomes Moreira, A., Kampik, NB., Oberli, L., Mohebbi, N.,

Lu, X., Meima, ME., Danser, AH., and Wagner, CA., Colocalization of the (Pro)renin Receptor/Atp6ap2 with H+-ATPases in Mouse Kidney but Prorenin Does Not Acutely Regulate Intercalated Cell H+-ATPase Activity. PLoS One., 11(1):e0147831.

13.Lu, X., Meima, M., et al., Identification of the (Pro)renin receptor as a Novel Regulator of Lipoprotein Metabolism. Circ Res. 2016. 118(2):222-9.

14.Lu, X., Krop, M., et al., Renin inhibitor VTP-27999 differs from aliskiren: focus on their intracellular accumulation and the (pro)renin receptor. J Hypertens, 2014. 32(6):1255-63.

15.Lu, X., L.C. Roksnoer, and A.H. Danser, The intrarenal renin-angiotensin system: does it exist? Implications from a recent study in renal angiotensin-converting enzyme knockout mice. Nephrol Dial Transplant, 2013. 28(12): p. 2977-82.

16.Persson, F*., Lu X* et al., Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? J Hypertens, 2013. 31(8): p. 1646-52. *: Joint first authors.

17.Lu, X., et al., (Pro)renin receptor is required for prorenin-dependent and -independent regulation of

vacuolar H(+)-ATPase activity in MDCK.C11 collecting duct cells. Am J Physiol Renal Physiol, 2013. 305(3): p. F417-25.

18.Krop, M., Lu X, et al., New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin. Hypertension, 2013. 61(5): p. 1075-82.  

19.Krop, M., Lu X, et al., The (pro)renin receptor. A decade of research: what have we learned?

Pflugers Arch, 2013. 465(1): p. 87-97.

20.Batenburg, W.W., Lu X, et al., Renin- and prorenin-induced effects in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually occur? Hypertension, 2011. 58(6): p. 1111-9.  

21.Lu, X., A.H. Danser, and M.E. Meima, HRP and prorenin: focus on the (pro)renin receptor and vacuolar H+-ATPase. Front Biosci (Schol Ed), 2011. 3: p. 1205-15.